Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone45-7022-2244
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$12.50 million
Profitability
Miscellaneous
Employees216
Next Earnings Date11/27/2019 (Estimated)
OptionableOptionable
Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions
What is Ascendis Pharma A/S's stock symbol?
Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."
How were Ascendis Pharma A/S's earnings last quarter?
Ascendis Pharma A/S (NASDAQ:ASND) posted its earnings results on Wednesday, August, 28th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.32) by $0.08. The biotechnology company had revenue of $3.61 million for the quarter, compared to the consensus estimate of $0.68 million. Ascendis Pharma A/S had a negative net margin of 932.52% and a negative return on equity of 35.99%. View Ascendis Pharma A/S's Earnings History.
When is Ascendis Pharma A/S's next earnings date?
What price target have analysts set for ASND?
8 analysts have issued 1-year target prices for Ascendis Pharma A/S's shares. Their predictions range from $90.00 to $191.00. On average, they expect Ascendis Pharma A/S's stock price to reach $147.00 in the next twelve months. This suggests a possible upside of 54.6% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.
What is the consensus analysts' recommendation for Ascendis Pharma A/S?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.
What are Wall Street analysts saying about Ascendis Pharma A/S stock?
Here are some recent quotes from research analysts about Ascendis Pharma A/S stock:
- 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (8/27/2019)
- 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Ascendis Pharma (ASND) with an Overweight rating and 12-mo. PT of $102. Ascendis is a pro-drug platform company based in Denmark that focuses on endocrinology-based rare diseases. The company leverages its novel pro-drug platform, TransCon™ to improve & extend duration of de-risked clinical-stage drugs’s action in the body. The company has upcoming Ph3 in its lead asset TransCon hGH, for treating growth hormone, expected in 1Q. We remain confident in clinical success of TransCon hGH, which should drive a first leg of upside in 2019. We also think that investors will assign more credit to the platform, especially TransCon PTH with Ph2 data expected YE2019." (1/23/2019)
Has Ascendis Pharma A/S been receiving favorable news coverage?
News headlines about ASND stock have been trending negative on Monday, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Ascendis Pharma A/S.
Who are some of Ascendis Pharma A/S's key competitors?
Some companies that are related to Ascendis Pharma A/S include Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Perrigo (PRGO) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of Ascendis Pharma A/S own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include Neurocrine Biosciences (NBIX), Exelixis (EXEL), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO), InVitae (NVTA), Uniqure (QURE), Supernus Pharmaceuticals (SUPN), TG Therapeutics (TGTX), AbbVie (ABBV) and Merck & Co., Inc. (MRK).
Who are Ascendis Pharma A/S's key executives?
Ascendis Pharma A/S's management team includes the folowing people:
- Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)
- Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)
- Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)
- Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)
- Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58)
When did Ascendis Pharma A/S IPO?
(ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.
Who are Ascendis Pharma A/S's major shareholders?
Ascendis Pharma A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Henry James International Management Inc. (0.03%).
Which institutional investors are buying Ascendis Pharma A/S stock?
ASND stock was bought by a variety of institutional investors in the last quarter, including Henry James International Management Inc..
How do I buy shares of Ascendis Pharma A/S?
Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Ascendis Pharma A/S's stock price today?
One share of ASND stock can currently be purchased for approximately $95.09.
How big of a company is Ascendis Pharma A/S?
Ascendis Pharma A/S has a market capitalization of $4.01 billion and generates $12.50 million in revenue each year. The biotechnology company earns $-153,650,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe.View Additional Information About Ascendis Pharma A/S.
What is Ascendis Pharma A/S's official website?
How can I contact Ascendis Pharma A/S?
Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]
MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
